RAS network activation is common in human cancers, and in acute myeloid leukemia (AML) this activation is achieved mainly through gain-of-function mutations in KRAS, NRAS or the receptor tyrosine kinase FLT3. We show that in mice, premalignant myeloid cells harboring a Kras G12D allele retained low levels of Ras signaling owing to negative feedback involving Spry4 that prevented transformation. In humans, SPRY4 is located on chromosome 5q, a region affected by large heterozygous deletions that are associated with aggressive disease in which gain-of-function mutations in the RAS pathway are rare. These 5q deletions often co-occur with chromosome 17 alterations involving the deletion of NF1 (another RAS negative regulator) and TP53. Accordingly, combined suppression of Spry4, Nf1 and p53 produces high levels of Ras signaling and drives AML in mice. Thus, SPRY4 is a tumor suppressor at 5q whose disruption contributes to a lethal AML subtype that appears to acquire RAS pathway activation through a loss of negative regulators.
RAS network activation is common in human cancers, and in acute myeloid leukemia (AML) this activation is achieved mainly through gain-of-function mutations in KRAS, NRAS or the receptor tyrosine kinase FLT3. We show that in mice, premalignant myeloid cells harboring a Kras G12D allele retained low levels of Ras signaling owing to negative feedback involving Spry4 that prevented transformation. In humans, SPRY4 is located on chromosome 5q, a region affected by large heterozygous deletions that are associated with aggressive disease in which gain-of-function mutations in the RAS pathway are rare. These 5q deletions often co-occur with chromosome 17 alterations involving the deletion of NF1 (another RAS negative regulator) and TP53. Accordingly, combined suppression of Spry4, Nf1 and p53 produces high levels of Ras signaling and drives AML in mice. Thus, SPRY4 is a tumor suppressor at 5q whose disruption contributes to a lethal AML subtype that appears to acquire RAS pathway activation through a loss of negative regulators.
AML is a heterogeneous cancer that represents the most common form of acute leukemia in adults 1 . Cytogenetic and molecular profiling of human AML samples has identified a range of missense mutations, translocations and large chromosomal events that can be associated with different patient outcomes 2, 3 . Among the most common genetic events in AML are gain-of-function mutations in the RAS pathway, including activating mutations of KRAS and NRAS or of the upstream receptor tyrosine kinases FLT3 and KIT 2, 3 . Each of these mutations produces altered proteins that directly or indirectly drive RAS GTPase into a constitutively active GTP-bound state 4 and leads to constitutive activation of the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways 4 . Although these lesions are considered important drivers of disease, RAS mutations alone are often unable to produce the high levels of MAPK and PI3K signaling necessary for malignant transformation without an increase in the copy number of mutant KRAS or NRAS or other mechanisms that enhance RAS output [5] [6] [7] .
Previously, we found that activation of Kras via the Kras G12D allele cooperates with RNA interference (RNAi)-mediated Trp53 inactivation to induce AML in mice 8 , and the AML cells had markedly elevated amounts of phosphorylated Erk (pErk; a MAPK effector) and S6 (pS6; an effector of both the MAPK and PI3K pathways) in both primary leukemia and transplanted secondary AML, even in the absence of stimulation by cytokine granulocyte-macrophage colonystimulating factor (GM-CSF) (Fig. 1a,b) 8 . However, consistent with previous work 5, 6, 9, 10 , Kras G12D alone was unable to trigger a basal or cytokine-induced increase in the abundance of pErk or pS6 in bulk bone marrow cells, Kit + progenitors or Mac-1 + mature myeloid cells as assessed by flow cytometry (Fig. 1a,b and Supplementary  Fig. 1a-d) . Thus, although highly activated Ras signaling appears to be an intrinsic feature of these AML cells, endogenous expression of oncogenic Kras G12D is insufficient to sustain constitutive activation of downstream effectors in non-transformed myeloid cells. Although in some systems high pErk levels can be achieved via somatic duplication or amplification of the Kras G12D allele 5, 6 , these events cannot explain the strong pathway activation that occurred in our AML model, as no increase in Kras G12D allele balance 8 or corresponding protein levels was observed (Supplementary Fig. 1e) .
It is well established that Ras activation can trigger compensatory feedback mechanisms that dampen signaling output [11] [12] [13] . To test whether such mechanisms might modulate Ras signaling during leukemogenesis, we generated wild-type or Kras G12D-expressing hematopoietic stem and progenitor cells (HSPCs) by transducing wild-type or Lox-Stop-Lox transcriptional silencing cassette (LSL)-Kras G12D fetal liver cells with a vector encoding GFP-coupled, self-deleting Cre ER (LGmCreER) 8 . After adding tamoxifen to induce Cre activity and thereby activate the Kras G12D allele 8 , we quantified the expression Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis l e t t e r s of ten known Ras negative-feedback genes 11 in GFP + cells expressing myeloid markers (Supplementary Fig. 1f ). Quantitative RT-PCR (qRT-PCR) analysis showed that Spry4 was significantly upregulated by mutant Kras expression (Fig. 1c) but underexpressed in Kras G12D leukemia cells with knockdown of Trp53 compared to normal bone marrow cells (Fig. 1d) .
The inverse correlation between Spry4 expression and Ras effector pathway activation was particularly interesting given the role of Sprouty proteins as negative regulators of Ras-MAPK signaling during development 14 . To test whether Spry4-mediated feedback limits Rasinduced leukemogenesis, we used the established transplantation-based approach to assess the effect of Spry4 suppression on Kras G12D -induced leukemogenesis 8, 15 . In this approach, control and Spry4 short hairpin RNAs (shRNAs) (Supplementary Fig. 2a,b) were transduced into LSL-Kras G12D HSPCs using the LGmCreER vector, and the resulting cells were treated with tamoxifen to activate Kras G12D . Mice receiving HSPCs transduced with each of three Spry4 shRNAs displayed accelerated onset of T cell lymphoma driven by oncogenic Kras 16, 17 ( Supplementary Fig. 2b) . Thus, Spry4 suppression cooperated with Kras G12D activation during tumorigenesis.
To assess whether Spry4 can also limit the development of myeloid neoplasia, we biased the system against lymphoid disease by using C57BL/6J athymic mice (Foxn1 nu ) as recipients. In these studies, we transduced two of the validated Spry4 shRNAs into LSL-Kras G12D ; Trp53 +/− HSPCs, anticipating loss of the wild-type Trp53 allele during leukemogenesis. Again, both Spry4 shRNAs accelerated disease onset (Fig. 2a) (median survival of 112 and 215 d for recipients of Kras G12D ; Trp53 +/− HSPCs with knockdown of Spry4 (KP-S HSPCs) and Kras G12D ; Trp53 +/− HSPCs with knockdown by a control shRNA (KP-C HSPCs), respectively; P < 0.01). Interestingly, Trp53 remained intact in both KP-S and KP-C malignancies, which suggests that p53 can function as a haploinsufficient tumor suppressor in this model (Supplementary Fig. 2c ). Histopathological analyses of moribund animals showed that all KP-S and KP-C recipient mice developed histiocytic sarcoma, an aggressive tumor of monocyte-derived cells that manifests in spleen and liver ( Fig. 2b and Supplementary Fig. 3a) . Flow cytometry indicated that the spleens of KP-S recipients were massively enriched for cells expressing intermediate amounts of the myeloid marker Mac-1 ( Fig. 2c) and that these cells showed elevated amounts of both pErk and pS6, with elevation exacerbated by serum stimulation (Fig. 2c) . Notably, neoplastic cells isolated from two independent KP-S mice induced secondary disease in sublethally irradiated recipient mice at 100% penetrance ( Supplementary Fig. 3b ). These results demonstrate that Spry4 knockdown accelerates oncogenesis and potentiates Kras-mediated myeloid transformation by increasing Ras signaling output.
In humans, SPRY4 is located at chromosome 5q31.3 and is frequently deleted in the context of del(5q) in patients with myelodysplastic syndrome (MDS), complex-karyotype AML and therapy-related myeloid neoplasms (t-MNs) [18] [19] [20] . Analysis of data from The Cancer Genome Atlas (TCGA) 2, 21, 22 showed that SPRY4 was deleted in 17 of 187 patients with AML (9% overall deletion rate) as part of chromosome 5q (Fig. 3a) . These findings were confirmed in a separate cohort of 35 subjects with AML or t-MNs. Here SPRY4 deletion, defined by SNP array analysis, was found in 12 of 13 samples with karyotyping-confirmed 5q abnormalities, as well as in one other sample with unknown cytogenetic information (Fig. 3a) . These observations, together with our functional studies, suggest a role for SPRY4 in human leukemia.
Although the action of oncogenic Kras and suppression of Spry4 can cooperate during tumorigenesis, KRAS and NRAS mutations rarely occur in human del(5q) AML 23, 24 . Indeed, whereas 42% of human AML samples show gain-of-function RAS pathway mutations (KRAS, NRAS, FLT3 and/or KIT), such mutations were significantly under-represented in individuals with del(5q) AML harboring SPRY4 deletion (only 3 of 17; Fisher's exact test, P = 0.025). Instead, SPRY4-encompassing del(5q) often co-occurred with TP53 mutations and/or deletion of the TP53 locus on chromosome 17p ( Fig. 3b and Supplementary Figs. 4 and 5a,b; P < 0.0005). In addition to deletion of SPRY4, del(5q) AML frequently harbors losses of other negative RAS regulators, including RASA1 (encoding p120-RasGAP; 5q), DUSP1 (5q), DUSP14 (17q) and NF1 (17q) ( Fig. 3b and Supplementary Figs. 4 and 5 ; odds ratio > 10, P < 0.0005 for l e t t e r s all combinations by cBioPortal; see URLs). Interestingly, analysis of transcriptional profiles showed significant overlap between gene ontology categories enriched in AML with SPRY4-encompassing 5q deletion and those enriched in NRAS-mutant AML (six overlapping pathways: five downregulated and one upregulated; P = 1.7 × 10 −5 ) (Supplementary Fig. 6a ). In addition, these del(5q) AMLs with SPRY4 loss displayed a gene set enrichment signature and a global gene expression pattern similar to that of AML harboring NRAS or KRAS mutations (Supplementary Fig. 6b,c) . These results suggest that del(5q) AML may acquire RAS pathway activation through the combined loss of negative regulators, rather than through mutational activation of a single pathway component. We next tested whether combined inhibition of Ras negative regulators could drive AML in the absence of an activated Ras allele. Given the significant co-occurrence of SPRY4, NF1 and TP53 deletions in del(5q) AML (P < 0.0001; Supplementary Fig. 5b) , we chose to cosuppress Spry4 and Nf1 in a Trp53-null background using the HSPC transduction and transplantation system described above. In this iteration, we knocked down either Nf1 (Nf1 shRNA-mCherry) or Spry4 (Spry4 shRNA-GFP) along with Renilla luciferase (Ren) (control shRNA coupled to a molecule of the opposite color 25 ), or we knocked down expression of these genes in combination in Trp53 −/− HSPCs (experimental design shown in Fig. 4a) . Interestingly, suppression of Nf1 alone led to the upregulation of Spry4 and vice versa (Supplementary Fig. 7a) , suggesting a mutual compensatory process that accounts for the cooccurring deletions of multiple genes in this pathway. Accordingly, the abundance of pErk and pS6 was significantly increased in 
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pErk pS6 Fig. 7b ). Thymectomized mice transplanted with Trp53 −/− HSPCs transduced with constructs for Nf1 and Spry4 shRNAs (Trp53 −/− ; shNf1; shSpry4 HSPCs) displayed accelerated leukemia onset compared with mice transplanted with any of the controls (Fig. 4b-d and Supplementary Fig. 8a ). The moribund mice harboring these cells presented with splenomegaly, increased white blood cell counts and anemia (Fig. 4b) , leading to reduced overall survival ( Fig. 4c; median survival of 42 d in recipients of cells with double knockdown of Nf1 and Spry4 compared to 78 d in recipients of cells with Nf1 knockdown only; P < 0.0001 versus control Ren shRNA, P = 0.0027 versus Nf1 shRNA). As expected, these Trp53 −/− ; shNf1; shSpry4 leukemia cells displayed high levels of Ras signaling ( Supplementary  Fig. 8b ). Histopathological analyses indicated that these animals displayed leukemic blasts in the peripheral blood, that their bone marrow and spleens had disrupted architecture, and that leukemia cells had disseminated into the liver and spleen (Fig. 4d) . Leukemic cells expressed modest levels of Gr-1, Mac-1 and Ter-119 but lacked expression of B220 and CD3ε, and they had an increased proportion of Lin − Kit + myeloid progenitors, consistent with an immature myeloid phenotype (Supplementary Fig. 9a,b) . Leukemic cells isolated from both bone marrow and spleen produced secondary malignancies identical to the primary disease when transplanted into sublethally irradiated recipients, whereas Trp53 −/− cells with Nf1 knockdown failed to do so within the same time frame (data not shown). Thus, co-suppression of Spry4 and Nf1 acts in a p53-deficient background to produce AML of an early hematopoietic phenotype with myeloid maturation.
The studies described above functionally validate a new tumor suppressor in del(5q) AML and, in doing so, provide insights into its etiology. Although CSNK1A1, RPS14, EGR1 and APC have been implicated as putative tumor suppressors on 5q, the mechanism(s) by which alterations in each contribute to leukemogenesis alone or in combination are not completely understood [26] [27] [28] [29] . Our finding that SPRY4 is frequently deleted together with other negative regulators of RAS signaling suggests that one way del(5q) can contribute to leukemogenesis is by augmenting flux through the RAS pathway. The lack of frequent mutation or silencing of the remaining allele for any gene in del(5q) deletions implies that tumor suppressors in this region are haploinsufficient 28, 29 . Accordingly, we found that the levels of Spry4 mRNA in Spry4-knockdown leukemia were halved ( Supplementary  Fig. 8c ). These findings are consistent with the emerging view that large chromosomal deletions contain multiple haploinsufficient tumor suppressors whose attenuation can functionally cooperate during tumorigenesis [30] [31] [32] .
In addition, our results suggest a mechanism for RAS pathway activation in del(5q) AML that may have broader relevance. In contrast to other AML subtypes in which RAS signaling is activated by mutation of the NRAS, KRAS or FLT3 oncogenes, del(5q) AML cells harbor losses of multiple RAS signaling negative regulatory genes that can functionally cooperate to achieve high levels of RAS pathway activation. The loss of multiple negative regulators may be necessary given the typically less potent induction of RAS activation by negative regulator loss 33 . In addition to SPRY4 and NF1, RASA1 (5q13), DUSP1 (5q34) and DUSP14 (17q12) are also frequently deleted in del(5q) AML and may have an important role in human disease progression. Previous work in lymphoma provides support for this model of tumor suppression, where combined haploinsufficiencies of genes in the same pathway, rather than two 'hits' in a single gene, can promote tumorigenesis 25 . Interestingly, we noted that additional cancer types with low rates of activating mutations in the RAS pathway, such as prostate adenocarcinoma (TCGA, provisional) 21, 22 and glioblastoma 34 , may contain deletions of multiple negative regulators that, in principle, may contribute to pathway activation in these tumor types (heterozygous and homozygous deletions of RAS negative regulators seen in 46.1% and 97.2% of cases, respectively). Thus a more thorough investigation of the functional consequences of these deletions is clearly warranted, particularly given that this could broaden patient stratification for RAS pathway-targeted therapies. 
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Methods and any associated references are available in the online version of the paper. 
